

# Bristi Basu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4101283/publications.pdf>

Version: 2024-02-01

87  
papers

2,169  
citations

257450

24  
h-index

254184

43  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3800  
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28960-28970.	7.1	150
2	Quantifying normal human brain metabolism using hyperpolarized [ <sup>13</sup> C]pyruvate and magnetic resonance imaging. NeuroImage, 2019, 189, 171-179.	4.2	144
3	Imaging breast cancer using hyperpolarized carbon-13 MRI. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2092-2098.	7.1	138
4	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 2020, 11, 4841.	12.8	129
5	Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM) Tj ETQq1 1 0.784314 rgBT /Over 298-306.	8.1	114
6	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	7.0	101
7	A phase I trial of the $\hat{I}^3$ -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	6.4	90
8	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- $\hat{I}^{\pm}$ , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clinical Cancer Research, 2020, 26, 3936-3946.	7.0	86
9	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non- $\hat{I}^{\pm}$ <i>BRCA1/2</i>-Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	9.4	82
10	Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocrine-Related Cancer, 2010, 17, R75-R90.	3.1	68
11	Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience. Clinical Cancer Research, 2012, 18, 3750-3761.	7.0	65
12	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical Cancer Research, 2020, 26, 1009-1016.	7.0	56
13	Targeting the DNA damage response in oncology. Current Opinion in Oncology, 2012, 24, 316-324.	2.4	52
14	Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. Journal of Translational Medicine, 2019, 17, 328.	4.4	51
15	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. Journal of Clinical Oncology, 2013, 31, 2580-2580.	1.6	50
16	Upregulation of C/EBP $\hat{I}^{\pm}$ Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	7.0	47
17	Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Oncology, 2015, 89, 281-287.	1.9	41
18	Intermittent schedules of the oral RAF $\hat{I}^{\pm}$ -MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncology, The, 2020, 21, 1478-1488.	10.7	41

#	ARTICLE	IF	CITATIONS
19	Hyperpolarized <sup>13</sup> C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Radiology Imaging Cancer</i> , 2020, 2, e200017.	1.6	40
20	Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 393-403.	2.8	38
21	PARP Inhibitors. <i>Drugs</i> , 2012, 72, 1579-1590.	10.9	36
22	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
23	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1583-1598.	2.4	26
24	Targeting IGF-1R: throwing out the baby with the bathwater?. <i>British Journal of Cancer</i> , 2011, 104, 1-3.	6.4	26
25	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1918-1925.	1.2	26
26	A phase 2 study of vatalanib in metastatic melanoma patients. <i>European Journal of Cancer</i> , 2010, 46, 2671-2673.	2.8	25
27	Early Phase Clinical Trial Designs – State of Play and Adapting for the Future. <i>Clinical Oncology</i> , 2017, 29, 770-777.	1.4	24
28	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3021-3021.	1.6	21
29	First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3004-3004.	1.6	21
30	Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2447-2449.	4.1	20
31	Targeting angiogenesis in melanoma: prospects for the future. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 367-380.	3.2	20
32	Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism. <i>British Journal of Radiology</i> , 2018, 91, 20170688.	2.2	20
33	The Role of Angiogenesis Inhibitors in the Management of Melanoma. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 32-49.	2.1	19
34	Imaging Glioblastoma Metabolism by Using Hyperpolarized [ <sup>13</sup> C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study. <i>Radiology Imaging Cancer</i> , 2022, 4, .	1.6	17
35	Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. <i>British Journal of Cancer</i> , 2012, 107, 1797-1800.	6.4	15
36	Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 977-984.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1760-1768.	6.4	14
38	PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5571-5571.	1.6	14
39	Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer. <i>Pancreas</i> , 2017, 46, 1314-1321.	1.1	13
40	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.5	13
41	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2503-2503.	1.6	12
42	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial. <i>Acta Oncologica</i> , 2020, 59, 1028-1035.	1.8	11
43	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. <i>Cancer Research</i> , 2016, 76, CT010-CT010.	0.9	11
44	A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. <i>Gynecologic Oncology</i> , 2006, 101, 4-11.	1.4	10
45	Perspectives in drug development for metastatic renal cell cancer. <i>Targeted Oncology</i> , 2010, 5, 139-156.	3.6	9
46	Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. <i>EJNMMI Research</i> , 2020, 10, 82.	2.5	9
47	Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570958.	2.8	8
48	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors – Results from the gastric cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 230-230.	1.6	8
49	LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors – Results from the colorectal cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3564-3564.	1.6	8
50	Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5547-5547.	1.6	7
51	PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). <i>Annals of Oncology</i> , 2016, 27, vi123.	1.2	6
52	Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP- $\beta$ in patients with advanced liver cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2509-2509.	1.6	6
53	Drug development and clinical trial design in pancreatico-biliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 73-94.	2.0	5
54	A phase I trial of the $\beta$ -secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4116-4116.	1.6	5

#	ARTICLE	IF	CITATIONS
55	EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOc).. Journal of Clinical Oncology, 2015, 33, TPS5605-TPS5605.	1.6	5
56	Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor (ER) or androgen receptor (AR) positive advanced breast carcinoma resistant to standard endocrine therapies.. Journal of Clinical Oncology, 2011, 29, 2525-2525.	1.6	4
57	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. European Journal of Cancer, 2011, 47, S159.	2.8	3
58	P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. Journal of Thoracic Oncology, 2017, 12, S1272-S1273.	1.1	3
59	Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, 2017, 28, v251-v252.	1.2	3
60	First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP- $\beta$ , in patients with advanced hepatocellular cancer (HCC). Annals of Oncology, 2019, 30, v168-v169.	1.2	3
61	Early derangement of INR predicts liver failure after liver resection for hepatocellular carcinoma. Journal of the Royal College of Surgeons of Edinburgh, 2022, , .	1.8	3
62	Intensive cisplatin/oral etoposide for epithelial ovarian cancer. Anti-Cancer Drugs, 2016, 27, 239-244.	1.4	2
63	STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. Annals of Oncology, 2019, 30, v267.	1.2	2
64	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2607-2607.	1.6	2
65	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology, 2017, 35, 4100-4100.	1.6	2
66	First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP- $\beta$ in patients with advanced liver cancer.. Journal of Clinical Oncology, 2017, 35, TPS2612-TPS2612.	1.6	2
67	TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials.. Journal of Clinical Oncology, 2022, 40, TPS3163-TPS3163.	1.6	2
68	Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials. Oncology, 2012, 83, 177-182.	1.9	1
69	Progress in pancreatic cancer: moving beyond gemcitabine?. Expert Review of Anticancer Therapy, 2012, 12, 997-1000.	2.4	1
70	Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013). Annals of Oncology, 2014, 25, iv156.	1.2	1
71	Scheduling Nab-Paclitaxel with Gemcitabine (Siege): Randomised Phase Ii Trial to Investigate Two Different Schedules of Nab-Paclitaxel (Abx) Combined with Gemcitabine (Gem) As First Line Treatment for Metastatic Pancreatic Adenocarcinoma (Pdac). Annals of Oncology, 2014, 25, iv252.	1.2	1
72	TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer. Annals of Oncology, 2016, 27, vi115.	1.2	1

#	ARTICLE	IF	CITATIONS
73	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 342-342.	1.6	1
74	Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study.. Journal of Clinical Oncology, 2020, 38, 499-499.	1.6	1
75	First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 554-554.	1.6	1
76	Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. , 2015, , .		1
77	Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. , 2015, , .		1
78	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 4601-4601.	1.6	1
79	A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2020, 38, 6043-6043.	1.6	1
80	1232 POSTER Creatinine Clearance (CrCl) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials. European Journal of Cancer, 2011, 47, S154.	2.8	0
81	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
82	Development of a prognostic model that predicts survival following Whipple's resection for ampullary adenocarcinoma.. Pancreatology, 2017, 17, S118.	1.1	0
83	Early derangement of the international normalized ratio (INR) predicts liver insufficiency following liver resection for hepatocellular carcinoma. Hpb, 2018, 20, S396-S397.	0.3	0
84	Systemic adjuvant therapies for breast cancer. , 2005, , 440-454.		0
85	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. Journal of Clinical Oncology, 2016, 34, 11530-11530.	1.6	0
86	Abstract B40: Evaluation of the combination of AZD2014 and olaparib in pancreatic cancer cells. , 2016, , .		0
87	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. Journal of Clinical Oncology, 2017, 35, 2571-2571.	1.6	0